Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Biomaterials. 2015 Oct 21;76:66–75. doi: 10.1016/j.biomaterials.2015.10.043

Figure 7.

Figure 7

pSMAD 1/5/8 inhibition reduces MP induced-mesenchymal morphology and MMP-2 activation. ESC aggregates were treated with pSMAD 1/5/8 inhibitor (LDH-193189) from day 3– day 14 of differentiation. (A) Morphology changes were evaluated by H&E staining on day 14 and (B) the expression levels of pro and active forms of MMP-2 were analyzed by zymography on days 7 and 10 of differentiation.